JPH0446950B2 - - Google Patents

Info

Publication number
JPH0446950B2
JPH0446950B2 JP59271603A JP27160384A JPH0446950B2 JP H0446950 B2 JPH0446950 B2 JP H0446950B2 JP 59271603 A JP59271603 A JP 59271603A JP 27160384 A JP27160384 A JP 27160384A JP H0446950 B2 JPH0446950 B2 JP H0446950B2
Authority
JP
Japan
Prior art keywords
hydroxy
compound
methylethyl
methoxyphenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59271603A
Other languages
English (en)
Japanese (ja)
Other versions
JPS60208965A (ja
Inventor
Takeo Iwakuma
Akira Tsunashima
Ichiro Ikezawa
Takeyuki Takaichi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of JPS60208965A publication Critical patent/JPS60208965A/ja
Publication of JPH0446950B2 publication Critical patent/JPH0446950B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP59271603A 1983-12-24 1984-12-21 新規カルボスチリル誘導体及びその製法 Granted JPS60208965A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8334494 1983-12-24
GB838334494A GB8334494D0 (en) 1983-12-24 1983-12-24 Carbostyril derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP62132886A Division JPS6354362A (ja) 1983-12-24 1987-05-28 カルボスチリル化合物

Publications (2)

Publication Number Publication Date
JPS60208965A JPS60208965A (ja) 1985-10-21
JPH0446950B2 true JPH0446950B2 (OSRAM) 1992-07-31

Family

ID=10553866

Family Applications (2)

Application Number Title Priority Date Filing Date
JP59271603A Granted JPS60208965A (ja) 1983-12-24 1984-12-21 新規カルボスチリル誘導体及びその製法
JP62132886A Pending JPS6354362A (ja) 1983-12-24 1987-05-28 カルボスチリル化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP62132886A Pending JPS6354362A (ja) 1983-12-24 1987-05-28 カルボスチリル化合物

Country Status (10)

Country Link
US (2) US4579854A (OSRAM)
EP (1) EP0147719B1 (OSRAM)
JP (2) JPS60208965A (OSRAM)
AT (1) ATE44954T1 (OSRAM)
CA (1) CA1258859A (OSRAM)
DE (1) DE3479119D1 (OSRAM)
GB (1) GB8334494D0 (OSRAM)
HK (1) HK89790A (OSRAM)
MY (1) MY101891A (OSRAM)
SG (1) SG75290G (OSRAM)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677112A (en) * 1984-02-02 1987-06-30 Warner-Lambert Company 1,2,3,4-tetrahydro-2-oxo-8-quinolineacetic and -propanoic acids and derivatives as cognition activators
US4687776A (en) * 1986-10-24 1987-08-18 Warner-Lambert Company Drug stabilization
JP2839847B2 (ja) * 1993-10-21 1998-12-16 大塚製薬株式会社 インターロイキン−８産生抑制剤
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
PT1393721E (pt) 1997-03-20 2009-02-02 Schering Corp Forma de dosagem de aglomerados de pó
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
DE60332321D1 (de) * 2002-03-01 2010-06-10 Chiesi Farma Spa Ultrafeine zusammensetzungen von formoterol
US6747043B2 (en) 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
EP1651224B1 (en) * 2003-07-31 2011-10-05 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050059643A1 (en) * 2003-08-05 2005-03-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a steroid and a betamimetic
CA2534693A1 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
SE0303179D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
KR20070000476A (ko) * 2004-02-27 2007-01-02 키에시 파르마슈티시 엣스. 피. 에이. 압축화 계량된 도스흡입용 안정된 약제용액 제제
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1574501A1 (en) * 2004-03-11 2005-09-14 Pfizer Limited Quinolinone derivatives, pharmaceutical compositions containing them and their use
WO2005092861A1 (en) * 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
PE20060159A1 (es) * 2004-03-24 2006-04-04 Chiesi Farma Spa Monoclorhidrato de 8-hidroxi-5-[(1r)-1-hidroxi-2-{[(1r)-2-(4-metoxifenil)-1-metiletil]amino}etil]-2-(1h)-quinolinona en forma cristalina y el proceso para su preparacion
US7307076B2 (en) * 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
RU2006146042A (ru) 2004-06-03 2008-07-20 Тереванс Диаминные агонисты 2-адренергических рецепторов
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
EP1786762A2 (en) 2004-09-10 2007-05-23 Theravance, Inc. Amidine substituted aryl aniline compounds
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2006128847A2 (en) * 2005-05-31 2006-12-07 Boehringer Ingelheim International Gmbh Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
CN101198313A (zh) * 2005-08-01 2008-06-11 奇斯药制品公司 通过喷雾施用的包含长效β2－激动剂的药物制剂
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
US20090298875A1 (en) * 2005-08-26 2009-12-03 Astrazeneca Ab A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2009543658A (ja) * 2006-07-14 2009-12-10 アストラゼネカ・アクチエボラーグ 乾燥粉末状の薬を投与するための吸入装置及び配送装置
JP2009543860A (ja) 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
RU2009120229A (ru) 2006-12-19 2011-01-27 Астразенека Аб (Se) Производные хинуклидинола в качестве антагонистов мускариновых рецепторов
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
AU2008215924B2 (en) * 2007-02-15 2011-04-21 Pulmagen Therapeutics (Synergy) Limited Heterocyclic derivatives as M3 muscarinic receptors
AU2008220617B2 (en) * 2007-02-28 2012-12-06 Cipla Limited Process for preparing isomers of carmoterol
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2116537A1 (en) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
RU2010147881A (ru) * 2008-05-13 2012-06-20 Астразенека Аб (Se) ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА
AU2008356409B2 (en) * 2008-05-13 2012-01-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
JP5607032B2 (ja) 2008-05-27 2014-10-15 アストラゼネカ・アクチエボラーグ フェノキシピリジニルアミド誘導体およびｐｄｅ４仲介疾患状態におけるその使用
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
EP2360147A1 (en) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
WO2011136754A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
WO2011136752A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
WO2011136753A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
GB2484977A (en) * 2010-10-29 2012-05-02 Biocopea Ltd Treatment of a Th-1 mediated disease
MX2013009767A (es) 2011-02-25 2013-10-01 Irm Llc Compuestos y composiciones como inhibidores de trk.
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
JPWO2013011999A1 (ja) * 2011-07-20 2015-02-23 株式会社カネカ 光学活性２−メチルプロリン誘導体の製造法
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
WO2013077830A1 (en) 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CZ306252B6 (cs) * 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE354279B (OSRAM) * 1969-06-13 1973-03-05 Draco Ab
JPS5156464A (ja) * 1974-11-11 1976-05-18 Otsuka Pharma Co Ltd Karubosuchirirujudotaino seizoho
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
JPS6026784B2 (ja) * 1975-04-29 1985-06-25 樋口 佳成 新規カルボスチリル誘導体
JPS52283A (en) * 1975-06-23 1977-01-05 Otsuka Pharmaceut Co Ltd Process for preparation of carbostyril derivatives
JPS5913510B2 (ja) * 1975-12-26 1984-03-30 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノセイゾウホウ
JPS609713B2 (ja) * 1976-10-08 1985-03-12 大塚製薬株式会社 カルボスチリル誘導体
JPS5913510A (ja) * 1982-07-14 1984-01-24 Kotobuki Sangyo Kk 冷却誘導案内装置

Also Published As

Publication number Publication date
JPS6354362A (ja) 1988-03-08
GB8334494D0 (en) 1984-02-01
USRE33024E (en) 1989-08-15
DE3479119D1 (en) 1989-08-31
EP0147719A2 (en) 1985-07-10
CA1259074C (OSRAM) 1989-09-05
SG75290G (en) 1990-11-23
US4579854A (en) 1986-04-01
EP0147719B1 (en) 1989-07-26
HK89790A (en) 1990-11-09
EP0147719A3 (en) 1986-06-25
CA1258859A (en) 1989-08-29
ATE44954T1 (de) 1989-08-15
JPS60208965A (ja) 1985-10-21
MY101891A (en) 1992-02-15

Similar Documents

Publication Publication Date Title
JPH0446950B2 (OSRAM)
DE60320439T2 (de) INDOLDERIVATE ALS ß2-AGONISTEN
US4234595A (en) 3-Indolyl-tertiary butylaminopropanols
JPH0710837B2 (ja) ピペラジニルー複素環式化合物
IE913477A1 (en) Indole derivatives as antiallergy and antiinflammatory agents
JPH11139969A (ja) 医薬組成物
GB2140412A (en) Thiazolidine derivatives, process for the preparation and pharmaceutical compositions thereof
JPS638935B2 (OSRAM)
JPH1160557A (ja) アポｂ分泌／ｍｔｐ阻害剤の塩酸塩
KR890001375B1 (ko) 벤즈아미도 유도체의 제조 방법
JPH0567150B2 (OSRAM)
US4357333A (en) N-Substituted 2-(8-halo and trifluoromethyl 4-quinolylamino)benzamides and analgesic use thereof
JPS62267250A (ja) 抗不整脈剤
DK147854B (da) Analogifremgangsmaade til fremstilling af n-(1-benzylpiperid-4-yl)-benzamider
US6083987A (en) Phenylenediamine derivative, radical scavenger, brain-infarction depressant, and brain-edema depressant
US5179089A (en) Isoquinoline compounds, compositions and use
US4138482A (en) 3-Cyano-N-(N,N-dimethylaminopropyl)-iminodibenzyl and salts thereof
JPH10218861A (ja) 新規なフェネタノール誘導体又はその塩
LU82235A1 (fr) Phenylmorphanes, intermediaires et procedes de synthese, et leur utilisation therapeutique
JP2967231B2 (ja) １，４―チアジン誘導体
KR960007523B1 (ko) 4-아릴카르보닐-1-[(4-모르폴리닐)-저급-알킬]-1h-인돌, 그 제조 방법 및 이를 포함한 조성물
US4042584A (en) Ethynylaryl phenyl cyclopropyl thiazines and morpholines
JPH046711B2 (OSRAM)
JPH07304740A (ja) カルボスチリル誘導体
JP2720549B2 (ja) ９―アミノアセチルアミノテトラヒドロアクリジン誘導体

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term